Our drug development company is committed to the commercialization of our proprietary proteins for the treatment of debilitating infectious diseases and for the better health of mankind.
Our flagship compound ITV-1 (Immune Therapeutic Vaccine) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS and Hepatitis C and to modulate the immune system.
IPF appears to modulate helper T1 cells’ expression of elaborate cytokines INF-γ, IL-2, which selectively promote cell-mediated immune response and subsequently stimulate cytotoxic lymphocytes. These lymphocytes have a prominent role in the host’s immunologic response to HIV infection. Proteins encoded by these pathogens enter the endogenous pathway for antigen presentation and are expressed on the surface of the infected cell as a complex with class I MHC – proteins. IPF appears to present a novel mechanism to reduce viral burden and stimulate innate immune responses to the virus for patients with significant antiretroviral resistance.